The integration of viral cDNA into the host genome is an essential step in the HIV‐1‐life
cycle and is mediated by the virally encoded enzyme, integrase (IN). Inhibition of this …

Abstract HIV‐1 integrase (IN) catalyzes the integration of proviral DNA into the host genome,
an essential step for viral replication. Inhibition of IN catalytic activity provides an attractive …

From the discovery of HIV-1 integrase (IN) inhibitors using enzyme-based assays in 1992, it
has taken 15 years to achieve success in human clinical trials. Currently available …

In recent years, HIV‐1 integrase (IN) has become an attractive target for designing
antiretroviral agents. The first IN inhibitor approved for clinical use, raltegravir, has validated …

HIV-1 integrase (IN) is an essential enzyme for retroviral replication. It is involved in the
integration of HIV DNA into host chromosomal DNA. The unique properties of IN makes it an …

The prospect of HIV-1 integrase (IN) as a therapeutically viable retroviral drug target is on
the verge of realization. The observed preclinical and clinical performance of β-diketo …

Integration of viral DNA into host cell chromosomal DNA to form a provirus is an essential
step in the viral life cycle. This process is mediated by integrase (IN), a 32 KDa viral enzyme …

The arsenal of drugs in the fight against AIDS is rapidly diminishing as the HIV becomes
resistant to the available reverse transcriptase and protease inhibitors. After killing millions …

HIV-1 integrase (IN) is an essential enzyme for effective viral replication and is a validated
target for the development of antiretroviral drugs. Currently, there are no approved drugs …

Background: HIV-1 integrase (IN) represents a therapeutically advantageous viral target to
treat HIV/AIDS in the clinic. Over a decade of progress in the field has resulted in IN inhibitor …